Source comparison
Tesamorelin + Ipamorelin vs Monotherapy: Timeline Comparison
Tesamorelin alone (2mg/day) 12–16 days 10–12 weeks 12–14 weeks (mean 14% reduction) Minimal (0.8–1.2 kg) Effective for visceral fat reduction but lacks anabolic component. Lipolysis without protein synthesis support Ipamorelin alone (200mcg/day) 10–14 days 8–1
This comparison does not assign a generated winner or score.
- Tesamorelin alone (2mg/day)
- 12–16 days
- 10–12 weeks
- 12–14 weeks (mean 14% reduction)
- Minimal (0.8–1.2 kg)
- Effective for visceral fat reduction but lacks anabolic component. Lipolysis without protein synthesis support
- Ipamorelin alone (200mcg/day)
- 10–14 days
- 8–10 weeks
- 14–16 weeks (mean 9% reduction)
- Moderate (1.5–2.1 kg)
- Stronger anabolic signal than Tesamorelin but weaker lipolytic effect. Better for lean mass, less effective for abdominal adiposity
- Tesamorelin + Ipamorelin blend
- 8–12 weeks
- 10–12 weeks (mean 18.4% reduction)
- Significant (2.6–3.4 kg)
- Synergistic effect produces faster and greater magnitude changes in both VAT and lean mass. The combination outperforms either peptide alone
- CJC-1295 + Ipamorelin
- 14–18 days
- 10–14 weeks
- 12–16 weeks (mean 12% reduction)
- Moderate (1.8–2.5 kg)
- Longer GH half-life extends duration but reduces peak amplitude. Slower onset, more sustained baseline elevation